Table 1.
| A: Patient characteristics by CHFR Expression | |||||
|---|---|---|---|---|---|
| Total | CHFR low |
CHFR high |
p- value* |
||
| N=41 (%) |
N=16 (%) |
N=25 (%) |
|||
| Age (years) | Median | 63 | 65 | 62 | 0.13 |
| Mean | 64 | 66 | 62.4 | ||
| SD | 7.7 | 8.8 | 6.7 | ||
| Race | Caucasian | 28 (68) | 12 (75) | 16 (64) | 0.46 |
| African American | 13 (32) | 4 (25) | 9 (36) | ||
| Sex | M | 40 (98) | 15 (94) | 25(100) | 0.39 |
| F | 1 (2) | 1 (6) | 0 | ||
| Treatment | CBCDA/TAX | 32 (78) | 12 (75) | 20 (80) | 0.72 |
| Bev/CBCDA/TAX | 9 (22) | 4 (25) | 5 (20) | ||
| ECOG PS | 0 | 11 (27) | 5 (31) | 6 (24) | 0.22 |
| 1 | 15 (37) | 8 (50) | 7 (28) | ||
| 2 | 6 (15) | 2 (13) | 4 (16) | ||
| 3 | 9 (22) | 1 (6) | 8 (32) | ||
| Response | CR | 1 (2) | 1 (6) | 0(0) | 0.034 |
| PR | 12 (29) | 4 (25) | 8 (32) | ||
| SD | 12 (29) | 8 (50) | 4 (16) | ||
| PD | 16 (39) | 3 (19) | 13 (52) | ||
| Squamous cell | |||||
| Histology | carcinoma (SCC) non-SCC |
9 (22) 32 (78) |
3 (19) 13 (81) |
6 (24) 19 (76) |
1.00 |
| Number of lines of additional therapy |
0 | 26 (63) | 9 (56) | 17 (68) | 0.22 |
| 1 | 10 (24) | 3 (19) | 7 (28) | ||
| 2 | 4 (10) | 3 (19) | 1 (4) | ||
| 3 | 1 (2) | 1 (6) | 0 (0) | ||
| Age-category | >=65 | 17 (41) | 8 (50) | 9 (36) | 0.38 |
| <65 | 24(59) | 8 (50) | 16 (64) | ||
| ECOG PS- category |
good | 26 (63) | 13 (81) | 13 (52) | 0.06 |
| poor | 15(37) | 3 (19) | 12 (48) | ||
| Response- category |
Clinical benefit | 25 (61) | 13 (81) | 12 (48) | 0.033 |
| Progression | 16 (39) | 3 (19) | 13 (52) | ||
| Time of diagnosis |
before 2005 | 14(34) | 5(31) | 9 (36) | 0.75 |
| 2005 and later | 27(66) | 11 (69) | 16 (64) | ||
| 2 or more lines of treatment |
no | 26 (63) | 9 (56) | 17 (68) | 0.446 |
| yes | 15 (37) | 7 (44) | 8 (32) | ||
| B: Patient characteristics of the validation set | |||||
|---|---|---|---|---|---|
| total | CHFR low | CHFR high | p- value* |
||
| 20 | 7 (%) | 13 (%) | |||
| Age | Mean | 67.4 | 61.5 | 0.3 | |
| Median | 69 | 66 | |||
| Race | C | 12 (60) | 4 (58) | 8 (62) | 1 |
| AA | 6 (30) | 2 (28) | 4 (31) | ||
| unknown | 2 (10) | 1 (14) | 1 (7) | ||
| Sex | M | 16 (80) | 5 (71.4) | 11 (84.6) | 0.48 |
| F | 4 (20) | 2 (28.6) | 2 (15.4) | ||
| Treatment | CDDP/TAX | 17 (85) | 5 (71) | 12 (70) | 0.33 |
| CDDP/TAX/Avastin | 3 (15) | 2 (29) | 1 (30) | ||
| ECOG PS | 0 | 4 (20) | 2 (29) | 2 (15) | 0.84 |
| 1 | 6 (30) | 2 (29) | 4 (31) | ||
| 2 | 6 (30) | 2 (29) | 4 (31) | ||
| unknown | 4 (20) | 1 (15) | 3 (23) | ||
| Histology | SCC | 1 (5) | 0 (0) | 1 (7.7) | 0.34 |
| non-SCC | 19 (95) | 7 (100) | 12 (92.3) | ||
| Clinical benefit |
yes | 11 (55) | 7 (100) | 4 (31) | 0.03 |
| non | 8 (40) | 0 (0) | 8 (62) | ||
| Unknown | 1 (5) | 0 (0) | 1 (7) | ||
| Time of diagnosis |
Before 2005 | 2 (10) | 1(14.3) | 1 (7.7) | 0.64 |
| After 2005 | 18 (80) | 6 (85.7) | 12 (92.3) | ||
| 2 or more lines of therapy |
yes | 3 (15) | 2(29) | 1(8) | |
| no | 17 (85) | 5(71) | 12(92) | 0.22 | |
*
The p-value is calculated by ANOVA for age in years; Fisher’s exact test for gender, treatment, ECOG PS, response, histology, and additional lines of treatment; Chi-sqaure test for the remaining categorical covariates; and log-rank test for survival.
*
The p-value is calculated by ANOVA for age in years; Fisher’s exact test for gender, treatment, ECOG PS, clinical benefit, histology